There is controversy over how best to treat patients after they've undergone surgery for prostate cancer. Does one wait until the cancer comes back or provide men with additional radiation therapy to prevent cancer recurrence? Now, a new study from Thomas Jefferson University shows that a genomic tool can help doctors and patients make a more informed decision.
What is prostate cancer? what causes prostate cancer? - Medical News Today
GenomeDx Biosciences' Decipher® Test Predicts Radiation Therapy Failure and Identifies Candidates for Early Radiation Therapy Following Prostate Surgery | GenomeDx
Genomic Prostate Cancer Classifier Predicts Biochemical Failure and Metastases in Patients After Postoperative Radiation Therapy - International Journal of Radiation Oncology • Biology • Physics
THE DECIPHER PROSTATE CANCER CLASSIFIER PREDICTS BIOCHEMICAL FAILURE IN PATIENTS FOLLOWING POST OPERATIVE RADIATION THERAPY Robert_Den_2.pdf
Genomic Analysis of Prostate Cancer Indicates Best Course of Action after Surgery - Thomas Jefferson University
No comments:
Post a Comment